A Phase 4 interventional study of Motivational Interviewing (MI) Counseling and Peer Mentoring in Human Immunodeficiency Virus (HIV) and Smoking Cessation, sponsored by New York University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by New York University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 921 studies in Smoking Cessation with a site in United States — 98 open to participants now, 127 under way, 7 of them phase 3. Smoking Cessation · United States.
Among the 921 studies in Smoking Cessation with a site in United States, this one is the 209th largest by planned enrollment of the 873 interventional ones that give a count, is one of 45 that started in 2024, is one of 99 in phase 4, reaches primary completion later than 100 of the 126 other live ones, and was the 852nd registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →98 of the 921 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
921 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 137 · Phase 3 91 · Phase 4 99
First in 1996; this study’s year is marked. 45 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 148 across the 873 interventional studies, 200 across the 45 observational. Of the 756 that completed or were terminated, 377 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 921 have an industry lead sponsor. The 10 most frequent:
New York University is the lead sponsor of 124 studies on the registry; 32 are open to participants now.
New York University has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
56 of the studies in Smoking Cessation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT00591175Memorial Sloan Kettering Cancer CenterA Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 56 to your calendar (.ics) → With an account.
Among the 921 studies in Smoking Cessation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study's long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV.
This study will utilize Multiphase Optimization Strategy (MOST) to optimize a smoking cessation treatment for HIV clinical care by directly targeting patient barriers to quitting and clinical care barriers to reaching and effectively treating a broad heterogeneous population of smokers living with HIV. The four intervention components will be aimed at barriers to quitting among smokers living with HIV and include Motivational Interviewing; Peer Mentoring; Text-messaging; Combination Nicotine Replacement Therapy. These components have shown promise in research but are under-utilized to help smokers living with HIV quit and have not been tested in an optimization trial. This study will also incorporate data to evaluate the fidelity, acceptability and feasibility of the interventions in the HIV clinical care context in order to identify the most cost-effective, sustainable and scalable tobacco treatment package for the care environment.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
This study's planned enrollment of 500 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Browse Smoking Cessation studies →New York University is the lead sponsor of 124 studies on the registry; 32 are open to participants now.
Compared within Smoking Cessation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the Core Component.
Participants will receive the Core Component and Combination-NRT intervention.
Drug: Combination NRT
Participants will receive the Core Component and Text Messaging intervention.
Behavioral: Skills-based Text Messaging
Participants will receive the Core Component as well as the Combination-NRT and Text Messaging interventions.
Behavioral: Skills-based Text Messaging · Drug: Combination NRT
Participants will receive the Core Component and Peer Mentoring intervention.
Behavioral: Peer Mentoring
Participants will receive the Core Component as well as the Combination-NRT and Peer Mentoring interventions.
Behavioral: Peer Mentoring · Drug: Combination NRT
Participants will receive the Core Component as well as the Text Messaging and Peer Mentoring interventions.
Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging
Participants will receive the Core Component as well as the Combination-NRT, Text Messaging and Peer Mentoring interventions.
Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging · Drug: Combination NRT
Participants will receive the Core Component and Motivational Interviewing Counseling intervention.
Behavioral: Motivational Interviewing (MI) Counseling
Participants will receive the Core Component as well as the Combination-NRT and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Drug: Combination NRT
Participants will receive the Core Component as well as the Text Messaging and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Skills-based Text Messaging
Participants will receive the Core Component as well as the Combination-NRT, Text Messaging and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Skills-based Text Messaging · Drug: Combination NRT
Participants will receive the Core Component as well as the Peer Mentoring and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring
Participants will receive the Core Component as well as the Combination-NRT, Peer Mentoring and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring · Drug: Combination NRT
Participants will receive the Core Component as well as the Text Messaging, Peer Mentoring and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging
Participants will receive the Core Component as well as the Combination-NRT, Text Messaging, Peer Mentoring, and Motivational Interview Counseling interventions.
Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging · Drug: Combination NRT
Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.
Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.
NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.
If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
Biochemically-validated 7-day point prevalence smoking abstinence among SLWH in HIV clinical care
Self-reported 7-day cigarette PPA (point prevalence abstinence), with biochemical verification of CO (carbon monoxide) ≤6 ppm and negative salivary cotinine
Time frame: 32 weeks
Self-reported 30-day PPA
Self-reported 30-day cigarette PPA (point prevalence abstinence)
Time frame: 32 weeks
Self-reported 7-day PPA
Self-reported 7-day cigarette PPA (point prevalence abstinence) with carbon monoxide verification (\<=6 ppm)
Time frame: 8 and 16 weeks
Self-reported 30-day PPA
Self-reported 30-day cigarette PPA (point prevalence abstinence)
Time frame: 8 and 16 weeks
Quit attempts
Number of quit attempts (of at least 24 hours) in last 7 days and since last assessment
Time frame: 8, 16, and 32 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Oct 2024 (actual). Primary completion is estimated for Jun 2028, 44 months after the start.
Of 53 non-industry phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 44 months is above that.
Counting every sponsor, half of 56 studies reached it within 35 months; a quarter within 21 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.